Optimal care of cardiovascular disease and type 2 diabetes patients: Shared responsibilities between the cardiologist and diabetologist

Stern, 1995, Diabetes and cardiovascular disease. The “common soil” hypothesis, Diabetes, 44, 369, 10.2337/diabetes.44.4.369 Haffner, 1998, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med, 339, 229, 10.1056/NEJM199807233390404 Beckman, 2002, Diabetes and atherosclerosis. Epidemiology, pathophysiology and management, JAMA, 287, 2570, 10.1001/jama.287.19.2570 Grundy, 2004, Definition of metabolic syndrome. Report of the NHLBI/AHA conference on scientific issues related to definition, Circulation, 109, 433, 10.1161/01.CIR.0000111245.75752.C6 McKinlay, 2000, US public health and the 21st century: diabetes mellitus, Lancet, 356, 757, 10.1016/S0140-6736(00)02641-6 Bartnik, 2002, Recognising and treating the diabetic patient in cardiovascular care, Eur J CV Nurs, 1, 171, 10.1016/S1474-5151(02)00034-8 Inoguchi, 2000, High incidence of silent myocardial ischaemia in elderly patients with non insulin-dependent diabetes mellitus, Diabetes Res Clin Pract, 47, 37, 10.1016/S0168-8227(99)00102-3 Stamler, 1993, Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434 Van Belle, 1997, Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels, Circulation, 96, 1454, 10.1161/01.CIR.96.5.1454 Silva, 1999, Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome, Am Heart J, 138, 446, 10.1016/S0002-8703(99)70146-8 Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405 Turner, 1998, Risk factors for coronary artery disease in non insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23), BMJ, 316, 823, 10.1136/bmj.316.7134.823 Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309–17. Adler, 2000, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study, BMJ, 321, 412, 10.1136/bmj.321.7258.412 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–13. Tuomilehto, 1999, Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators, N Engl J Med, 340, 677, 10.1056/NEJM199903043400902 Ginsberg, 2005, Regulation of plasma triglycerides in insulin resistance and diabetes, Arch Med Res, 36, 232, 10.1016/j.arcmed.2005.01.005 Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA, 285, 1585, 10.1001/jama.285.12.1585 Bloomfield Rubins, 2001, Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT), Circulation, 103, 2828, 10.1161/01.CIR.103.23.2828 Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 Colhoun, 2005, After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?, Lancet, 366, 1829, 10.1016/S0140-6736(05)67668-4 Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 Pyorala, 1997, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), Diabetes Care, 20, 614, 10.2337/diacare.20.4.614 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57. Blasetto, 2003, Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolaemic patients and in special population groups, Am J Cardiol, 91, 3C, 10.1016/S0002-9149(03)00003-1 Reasner, 2005, What is the most effective strategy for managing diabetic dyslipidaemia?, Atheroscler Suppl, 6, 21, 10.1016/j.atherosclerosissup.2005.06.005 Malmberg, 1999, Circulation, 99, 2626, 10.1161/01.CIR.99.20.2626 Norhammar, 2002, Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study, Lancet, 359, 2140, 10.1016/S0140-6736(02)09089-X Capes, 2000, Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview, Lancet, 355, 773, 10.1016/S0140-6736(99)08415-9 Stranders, 2004, Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus, Arch Intern Med, 164, 982, 10.1001/archinte.164.9.982 Malmberg, 1995, Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year, J Am Coll Cardiol, 26, 57, 10.1016/0735-1097(95)00126-K Malmberg, 1997, Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group, BMJ, 314, 1512, 10.1136/bmj.314.7093.1512 Malmberg, 2005, Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity, Eur Heart J, 26, 650, 10.1093/eurheartj/ehi199 Van den Berghe, 2001, Intensive insulin therapy in the critically ill patient, N Engl J Med, 345, 1359, 10.1056/NEJMoa011300 Barzilay, 2001, Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders, Diabetes Care, 24, 1233, 10.2337/diacare.24.7.1233 American Diabetes Association, 1998, Consensus development conference on the diagnosis of coronary heart disease in people with diabetes, Diabetes Care, 21, 1551, 10.2337/diacare.21.9.1551 Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med, 348, 383, 10.1056/NEJMoa021778 Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997;96:1761–9. Fox, 2004, Trends in cardiovascular complications of diabetes, JAMA, 292, 2495, 10.1001/jama.292.20.2495 Bartnik, 2004, The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart, Eur Heart J, 25, 1880, 10.1016/j.ehj.2004.07.027 Aguilar, 2004, Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial, Circulation, 110, 1572, 10.1161/01.CIR.0000142047.28024.F2